Oaklands Corporate Center
440 Creamery Way, Suite E
Exton, PA 19341
Nathan Tzodikov, Ph.D., President & CEO
Line or Service Checkpoint Genetics is developing pharmaceuticals to
preserve our cardiovascular health regardless of ones diet. The
companys products are for prevention of atherosclerosis, restenosis, myocardial infarct,
stroke, Alzheimers disease and Parkinsons disease. The product line
consists of safe and potent antioxident therapeutics, including the
companys lead clinical candidate, CPG-603.
Rights The company has a pending patent covering a family of
pharmaceutical compositions for several unrelated diseases. The President
and CEO is the inventor of the technology and has assigned the entire
rights to the company. The patent claims provide a competitive advantage
for pharmaceutical products, incorporating CPG-603. A portfolio of related
patents, differentiated by diseases and unique compositions of matter are
likely to be issued upon examination of the initial application,
strengthening the companys technology base.
Opportunities The worldwide prescription market for cholesterol lowering
agents was $8.5 billion in 1998 with annual growth projected and realized
at 30% per year. Mercks Mevacor and Warner-Lamberts Lipitor,
pharmaceutical products, dominated this market. A conservative market
share estimate for Checkpoint Genetics first year sales of $300 million
is based upon its mechanism of action, by inhibiting atherogenesis.
Initial growth is estimated at 40 to 50% per year during the first 2
years, with sales topping out at $700 million to $1 billion.
and Distribution The
company plans to license marketing rights to a fully integrated
multinational pharmaceutical company with a complementary product
franchise. Should such pharmaceutical companies attempt to lock out
favorable terms for licensing, Checkpoint Genetics will contract for
detailing and distribution with suitable subcontractors.
The company will not invest in plant and facilities for manufacture of
its first product. Contract manufacturers will be utilized.
The company knows of no direct competition for CPG-603 and our family of
proprietary pharmaceutical compositions. The following cardiovascular
agents are in late stage development and are included for completeness.